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OBJECTIVE: To assess productivity among children with un-
controlled asthma (UA) and their caregivers. METHODS: An
internet-based survey was administered to caregivers of children
aged 6–12 years with moderate to severe asthma (severity and
control based on NAEPP guidelines). The caregiver questionnaire
assessed pediatric asthma symptoms, activity limitation, social
functioning, and school attendance. Caregiver productivity was
assessed using the Work Productivity and Activity Impairment
(WPAI) Questionnaire. WPAI measures were calculated with
higher scores representing greater percent reduction in produc-
tivity. The chi-square test was used to assess differences in pro-
portions for school impairment between children with UA versus
controlled asthma (CA), and the two-sample t-test was used to
assess differences in the child’s absenteeism and caregiver’s WPAI
measures. RESULTS: A total of 473 caregivers completed the
survey; 360 were caregivers of children with UA and 113 for
children with CA. Compared with CA, children with UA had
signiﬁcantly greater absenteeism (5.5 days vs. 2.2 days,
P < 0.001) during the previous year and were signiﬁcantly more
likely to miss school-related activities or visit the health ofﬁce/
school nurse (P < 0.001 for both). Caregivers of children with
UA reported signiﬁcantly more absenteeism (15.4% vs. 7.8%,
P = 0.03), impairment while working (20.8% vs. 13.4%,
P = 0.0001), greater overall work productivity loss (25.5% vs.
16.0%, P = 0.0001), and signiﬁcantly greater activity impair-
ment (23.6% vs. 11.2%, P = 0.0001). CONCLUSION: Uncon-
trolled asthma was associated with signiﬁcant reduction in
school attendance and increased need for health services while at
school and impacted the caregiver’s work productivity. Funded
by Genentech, Inc. and Novartis Pharmaceuticals Corporation.
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OBJECTIVE: Asthma is a chronic debilitating condition. The
lack of asthma control may impact patients’ daily activities
including work productivity. The current study evaluated the
impact of uncontrolled asthma, as measured by the Asthma
Control Test (ACT), on work productivity/activity impairment in
a sample of US asthma patients. METHODS: Data from United
States 2006 National Health and Wellness Survey (NHWS), a
nationally representative Internet survey of patients’ (18 years)
self-reported health status, health care attitudes, resource utili-
zation, work productivity and activity impairment were used.
The current analysis included subjects with self-reported diagno-
sis of asthma. Asthma control was categorized by ACT score:
uncontrolled, 19; controlled, 20. The Work Productivity and
Activity Impairment (WPAI) Questionnaire, a validated scale was
used to measure absenteeism (ie, work time missed) and presen-
teeism (ie, impairment at work or reduced on-the-job effective-
ness). Analyses of work productivity loss were limited to those
who were employed full-time. Linear regression models were
used to control for potential confounders and determine the
impact of asthma control on productivity. RESULTS: Of 62,833
NHWS respondents, 4.42% had uncontrolled asthma and
4.65% had controlled asthma. In bivariate analyses, signiﬁcant
differences were noted for demographic variables, as well as for
measures of work productivity and activity impairment between
those with controlled asthma and those with uncontrolled
asthma Those with uncontrolled asthma were signiﬁcantly more
likely to be older, less educated and not married (p < . 001) vs.
those with controlled asthma. After controlling for confounders,
those with controlled asthma reported lower levels of absentee-
ism (B = -4.055, p < 0.001), presenteeism (B = -13.287, p <
0.001) overall work productivity loss (B = -10.818, p < 0.001),
and activity impairment (B = -16.423, p < 0.001). CONCLU-
SION: The extent of asthma control can have a signiﬁcant impact
on work productivity, including presenteeism and absenteeism.
Improvement in the level of asthma control is likely to reduce the
burden of asthma to employers.
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OBJECTIVE: To have a better understanding of the concept of
treatment satisfaction in the context of asthma and other
chronic diseases. To identify and review the content of existing
treatment satisfaction questionnaires and search for any evi-
dence of a link between satisfaction and other outcomes.
METHODS: A literature review was conducted using
MEDLINE (1996–2006), EMBASE (1996–2006), abstracts
from scientiﬁc conferences (ERS since 2003, ISOQOL since
2004) and the Mapi Research Trust databases. Articles on the
concept of treatment satisfaction were reviewed. Studies and
randomized clinical trials describing the development or use of
instruments assessing treatment satisfaction were selected for
analysis. RESULTS: Treatment satisfaction is a well-deﬁned
concept that applies to the evaluation of health care and treat-
ment. Treatment satisfaction questionnaires speciﬁc to asthma
(n = 14), different chronic diseases (n = 13) and generic satis-
faction questionnaires (n = 3) were identiﬁed. Asthma speciﬁc
questionnaires included 1 to 40 items and covered 24 speciﬁc
domains. The domain on “treatment characteristics and inhaler
features” was the most widely covered with 51 items, followed
by the domains on “effectiveness” and “discomfort” of treat-
ment with 24 and 16 items, respectively. The analysis of clinical
trials suggested potential links between 1) satisfaction and com-
pliance, and 2) satisfaction and intention to continue the treat-
ment. Empirical data showed that a satisfaction assessment
could be used to differentiate products when used appropri-
ately. CONCLUSION: Future objectives of clinical studies
could include the 1) identiﬁcation of the features of treatment
that contribute most to treatment satisfaction; 2) comparison
of satisfaction levels between treatments; and 3) investigation
of the relationship between satisfaction and compliance or
between multi-health outcomes such as Health-Related Quality
of Life, symptoms and satisfaction. The information obtained
from such studies could then be used to differentiate between
products, to adapt treatment strategies and to therefore
improve the overall management of asthma patients.
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